The Journey of Insulin Glargine
Engineering a 24-Hour Depot
Insulin glargine is a recombinant human insulin analogue engineered to be soluble at the acidic pH of its formulation but to precipitate into microcrystals upon injection into the neutral pH of subcutaneous tissue — forming an amorphous depot that dissolves slowly, delivering a nearly peakless, 24-hour basal insulin profile that mimics overnight and interprandial insulin secretion.
Absorção
Insulin glargine (pH 4.0 formulation) is administered exclusively
subcutaneously — intravenous administration of the acidic preparation would be dangerous. Upon
subcutaneous injection, the acidic solution is neutralized to physiological pH (7.4), causing the
glargine molecule to precipitate into microcrystalline aggregates at the injection site, forming a
subcutaneous depot. These microcrystals slowly dissolve and release monomeric/dimeric insulin
glargine into the interstitium, which then diffuses into capillaries and is absorbed systemically.
This dissolution kinetic — not absorption kinetics per se — determines the flat, prolonged plasma
profile. Absorption is also slowed by self-association of glargine hexamers mediated by zinc ions
in the formulation. Subcutaneous bioavailability is approximately 50-70% (similar to other
insulin preparations), with onset in 2-4 hours and a duration of action of approximately 20-24 hours
(up to 42 hours with Toujeo, the 300 U/mL concentrated formulation).
Distribuição
After dissolving from the subcutaneous depot, insulin glargine
circulates in blood and distributes primarily in the extracellular compartment. The volume of
distribution is approximately 0.1-0.3 L/kg for free insulin. Both glargine and its active
metabolites M1 and M2 bind the insulin receptor (IR) and insulin-like growth factor 1 receptor
(IGF-1R). Glargine itself has approximately 6-7-fold higher IGF-1R affinity than human insulin —
a structural concern that initially raised questions about mitogenic potential, though the M1
metabolite (the predominant circulating species) has IGF-1R affinity similar to human insulin.
Insulin does not cross the blood-brain barrier except in trace amounts via transcytosis. Distribution
to adipose tissue, liver, skeletal muscle, and other insulin-responsive tissues occurs through
binding to insulin receptors on cell surfaces.
Mecanismo de Ação
Insulin (and glargine's active metabolites) exerts effects by
binding and activating the insulin receptor (IR, INSR), a transmembrane receptor tyrosine kinase.
Insulin binding triggers dimerization, autophosphorylation of intracellular tyrosine kinases
(Tyr1158, Tyr1162, Tyr1163 in the IR beta subunit), and recruitment of insulin receptor substrate
(IRS-1, IRS-2) proteins. The PI3K-AKT signaling cascade mediates metabolic effects: AKT
phosphorylates AS160 (TBC1D4) to promote GLUT4 vesicle translocation to the plasma membrane
(glucose uptake in skeletal muscle and adipose), phosphorylates GSK3 to activate glycogen synthase
(glycogen synthesis in liver and muscle), and suppresses hepatic gluconeogenesis via FOXO1
phosphorylation and nuclear exclusion. The RAS-MAPK cascade mediates mitogenic effects (cell
growth and proliferation). The near-peakless glargine profile provides steady-state basal insulin
activity that suppresses hepatic glucose output overnight and between meals without causing
post-meal hypoglycemia.
Metabolismo
In subcutaneous tissue and then in circulation, insulin glargine
undergoes enzymatic cleavage at its C-terminal extensions. Glargine was engineered with two arginine
residues added to the B-chain C-terminus (B31 and B32) and an asparagine-to-glycine substitution
at A21. Cleavage of the two B-chain arginines by carboxypeptidases at the injection site and in
circulation generates the primary active metabolite M1 (glargine minus B31-Arg and B32-Arg),
which has a pharmacological profile (IR affinity, metabolic effect) virtually identical to human
insulin. M1 is further metabolized to M2 (minor). Hepatic and renal insulin-degrading enzyme (IDE)
and ubiquitous proteases (elastin, cathepsins) degrade insulin fragments. No CYP450 pathways are
involved; glargine is catabolized as a protein.
Excreção
Insulin and its degradation products are catabolized to amino acids
and small peptides throughout the body, primarily in the liver (~50%), kidney (~30%), and muscle.
The kidneys filter, reabsorb, and catabolize insulin in the proximal tubule. In renal impairment,
insulin clearance is reduced (less tubular catabolism), increasing insulin action and hypoglycemia
risk — requiring lower insulin doses in patients with CKD. The elimination half-life of circulating
glargine/M1 is approximately 12 hours (plasma concentration), but the pharmacodynamic duration
extends to 24 hours because the subcutaneous depot continues releasing drug. The Toujeo formulation
(300 U/mL) has an even flatter profile and longer duration (up to 36 hours) due to a smaller
depot surface area-to-volume ratio.
Significância Clínica
Insulin glargine is the most widely prescribed basal insulin globally,
used in both type 1 and type 2 diabetes. Once-daily injection (any time, same time daily) provides
basal insulin coverage. The ORIGIN trial showed glargine to be non-inferior to standard care for
cardiovascular outcomes in dysglycemia. Nocturnal hypoglycemia is significantly lower with glargine
compared to NPH insulin. The Toujeo (U-300) formulation demonstrates even less hypoglycemia and
more consistent coverage. Biosimilar insulin glargines (Basaglar, Semglee) are available at lower
cost. Local injection site reactions (lipohypertrophy with repeated injection at the same site)
can alter absorption unpredictably. Insulin-antibody formation is rare with modern recombinant
human insulin analogues.